Patent 7091202 was granted and assigned to Bristol-Myers Squibb on August, 2006 by the United States Patent and Trademark Office.
The invention encompasses compounds of Formula I, which are blockers of KCNQ channels. Blockers of KCNQ channels are known to enchance cognition in laboratory animals. The invention includes, salts, solvates, compositions, and methods of use